TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Prostran, Milica
AU  - Martinović, Žarko J.
AU  - Veličković, Ružica
AU  - Grabnar, Iztok
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1348
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach
VL  - 20
IS  - Supplement 3
SP  - S247
EP  - S248
DO  - 10.1016/S0924-977X(10)70310-2
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Pokrajac, Milena and Prostran, Milica and Martinović, Žarko J. and Veličković, Ružica and Grabnar, Iztok",
year = "2010",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach",
volume = "20",
number = "Supplement 3",
pages = "S247-S248",
doi = "10.1016/S0924-977X(10)70310-2"
}

Vučićević, K., Miljković, B., Pokrajac, M., Prostran, M., Martinović, Ž. J., Veličković, R.,& Grabnar, I.. (2010). Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 20(Supplement 3), S247-S248.
https://doi.org/10.1016/S0924-977X(10)70310-2

Vučićević K, Miljković B, Pokrajac M, Prostran M, Martinović ŽJ, Veličković R, Grabnar I. Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach. in European Neuropsychopharmacology. 2010;20(Supplement 3):S247-S248.
doi:10.1016/S0924-977X(10)70310-2 .

Vučićević, Katarina, Miljković, Branislava, Pokrajac, Milena, Prostran, Milica, Martinović, Žarko J., Veličković, Ružica, Grabnar, Iztok, "Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach" in European Neuropsychopharmacology, 20, no. Supplement 3 (2010):S247-S248,
https://doi.org/10.1016/S0924-977X(10)70310-2 . .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Petronijević, Marija
AU  - Pokrajac, Milena
AU  - Veličković, Ružica
AU  - Mrhar, Ales
AU  - Grabnar, Iztok
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1240
PB  - Springer, Dordrecht
C3  - Pharmacy World & Science
T1  - No effect of gender on carbamazepine elimination-population approach
VL  - 31
IS  - 1
SP  - 118
EP  - 119
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1240
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Petronijević, Marija and Pokrajac, Milena and Veličković, Ružica and Mrhar, Ales and Grabnar, Iztok",
year = "2009",
publisher = "Springer, Dordrecht",
journal = "Pharmacy World & Science",
title = "No effect of gender on carbamazepine elimination-population approach",
volume = "31",
number = "1",
pages = "118-119",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1240"
}

Vučićević, K., Miljković, B., Petronijević, M., Pokrajac, M., Veličković, R., Mrhar, A.,& Grabnar, I.. (2009). No effect of gender on carbamazepine elimination-population approach. in Pharmacy World & Science
Springer, Dordrecht., 31(1), 118-119.
https://hdl.handle.net/21.15107/rcub_farfar_1240

Vučićević K, Miljković B, Petronijević M, Pokrajac M, Veličković R, Mrhar A, Grabnar I. No effect of gender on carbamazepine elimination-population approach. in Pharmacy World & Science. 2009;31(1):118-119.
https://hdl.handle.net/21.15107/rcub_farfar_1240 .

Vučićević, Katarina, Miljković, Branislava, Petronijević, Marija, Pokrajac, Milena, Veličković, Ružica, Mrhar, Ales, Grabnar, Iztok, "No effect of gender on carbamazepine elimination-population approach" in Pharmacy World & Science, 31, no. 1 (2009):118-119,
https://hdl.handle.net/21.15107/rcub_farfar_1240 .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Petronijević, M.
AU  - Pokrajac, Milena
AU  - Veličković, Ružica
AU  - Grabnar, Iztok
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/896
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study
VL  - 17
IS  - Supplement 4
SP  - S261
EP  - S262
DO  - 10.1016/S0924-977X(07)70358-9
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Petronijević, M. and Pokrajac, Milena and Veličković, Ružica and Grabnar, Iztok",
year = "2007",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study",
volume = "17",
number = "Supplement 4",
pages = "S261-S262",
doi = "10.1016/S0924-977X(07)70358-9"
}

Vučićević, K., Miljković, B., Petronijević, M., Pokrajac, M., Veličković, R.,& Grabnar, I.. (2007). Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 17(Supplement 4), S261-S262.
https://doi.org/10.1016/S0924-977X(07)70358-9

Vučićević K, Miljković B, Petronijević M, Pokrajac M, Veličković R, Grabnar I. Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study. in European Neuropsychopharmacology. 2007;17(Supplement 4):S261-S262.
doi:10.1016/S0924-977X(07)70358-9 .

Vučićević, Katarina, Miljković, Branislava, Petronijević, M., Pokrajac, Milena, Veličković, Ružica, Grabnar, Iztok, "Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study" in European Neuropsychopharmacology, 17, no. Supplement 4 (2007):S261-S262,
https://doi.org/10.1016/S0924-977X(07)70358-9 . .

TY  - CONF
AU  - Brzaković, Branka
AU  - Pokrajac, Milena
AU  - Miljković, Branislava
AU  - Martinović, Žarko J.
AU  - Veličković, Ružica
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/972
PB  - Springer, Dordrecht
C3  - Pharmacy World & Science
T1  - Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy
VL  - 29
IS  - 5
SP  - 499
EP  - 499
UR  - https://hdl.handle.net/21.15107/rcub_farfar_972
ER  - 

@conference{
author = "Brzaković, Branka and Pokrajac, Milena and Miljković, Branislava and Martinović, Žarko J. and Veličković, Ružica",
year = "2007",
publisher = "Springer, Dordrecht",
journal = "Pharmacy World & Science",
title = "Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy",
volume = "29",
number = "5",
pages = "499-499",
url = "https://hdl.handle.net/21.15107/rcub_farfar_972"
}

Brzaković, B., Pokrajac, M., Miljković, B., Martinović, Ž. J.,& Veličković, R.. (2007). Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy. in Pharmacy World & Science
Springer, Dordrecht., 29(5), 499-499.
https://hdl.handle.net/21.15107/rcub_farfar_972

Brzaković B, Pokrajac M, Miljković B, Martinović ŽJ, Veličković R. Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy. in Pharmacy World & Science. 2007;29(5):499-499.
https://hdl.handle.net/21.15107/rcub_farfar_972 .

Brzaković, Branka, Pokrajac, Milena, Miljković, Branislava, Martinović, Žarko J., Veličković, Ružica, "Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy" in Pharmacy World & Science, 29, no. 5 (2007):499-499,
https://hdl.handle.net/21.15107/rcub_farfar_972 .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Milijković, Branislava
AU  - Veličković, Ružica
AU  - Pokrajac, Milena
AU  - Mrhar, Ales
AU  - Grabnar, Iztok
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/898
AB  - The aim of the present study was to develop a population pharmacokinetic model of carbamazepine from routine therapeutic drug monitoring data. Steady-state carbamazepine plasma concentrations determined by homogenous enzyme immunoassay technique, dosing history including cotherapy, schedule of blood sampling, and patients' demographic characteristics were collected retrospectively from patients' chart histories. A one-compartment model was fitted to the data using nonlinear mixed effects modeling. The influence of weight, age, gender, smoking, allergy, carbamazepine daily dose, and cotherapy on clearance (CL/F) was evaluated. Additionally, bioavailability of controlled-release relative to immediate-release tablets was assessed. Two hundred sixty-five patients (423 concentrations) were used to develop a population pharmacokinetic model. The population estimate of CL/F from the base model was 5.14 L/h with interindividual variability of 50.20%. Patients' gender, age, smoking, allergy, cotherapy with lamotrigine and benzodiazepines had no effect on CUE Patient weight (WT), daily carbamazepine dose (DCBZ), daily dose of phenobarbitone (DPB) and valproic acid (VPA), when its daily dose exceeded 750 mg, significantly influenced CL/F and were included in the final model: CL/F [L/h] = 5.35 (DCBZ [mg/da/kg]/15)(0.591) (1 + 0.414 (DPB [mg/day/kg]/2) (WT [kg]/70)(0.564) 1.18(VPA) where VPA is 1 if dose is greater than 750 mg or 0 otherwise. No difference in bioavailability of carbamazepine between controlled and immediate-release tablets was detected. The model predictions in the validation set had no bias and satisfactory precision. The model can be used for estimation of carbamazepine CL/F in individual patients in the postautoinduction phase and for selection of optimum dosing regimen in routine patient care.
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Therapeutic Drug Monitoring
T1  - Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data
VL  - 29
IS  - 6
SP  - 781
EP  - 788
UR  - https://hdl.handle.net/21.15107/rcub_farfar_898
ER  - 

@article{
author = "Vučićević, Katarina and Milijković, Branislava and Veličković, Ružica and Pokrajac, Milena and Mrhar, Ales and Grabnar, Iztok",
year = "2007",
abstract = "The aim of the present study was to develop a population pharmacokinetic model of carbamazepine from routine therapeutic drug monitoring data. Steady-state carbamazepine plasma concentrations determined by homogenous enzyme immunoassay technique, dosing history including cotherapy, schedule of blood sampling, and patients' demographic characteristics were collected retrospectively from patients' chart histories. A one-compartment model was fitted to the data using nonlinear mixed effects modeling. The influence of weight, age, gender, smoking, allergy, carbamazepine daily dose, and cotherapy on clearance (CL/F) was evaluated. Additionally, bioavailability of controlled-release relative to immediate-release tablets was assessed. Two hundred sixty-five patients (423 concentrations) were used to develop a population pharmacokinetic model. The population estimate of CL/F from the base model was 5.14 L/h with interindividual variability of 50.20%. Patients' gender, age, smoking, allergy, cotherapy with lamotrigine and benzodiazepines had no effect on CUE Patient weight (WT), daily carbamazepine dose (DCBZ), daily dose of phenobarbitone (DPB) and valproic acid (VPA), when its daily dose exceeded 750 mg, significantly influenced CL/F and were included in the final model: CL/F [L/h] = 5.35 (DCBZ [mg/da/kg]/15)(0.591) (1 + 0.414 (DPB [mg/day/kg]/2) (WT [kg]/70)(0.564) 1.18(VPA) where VPA is 1 if dose is greater than 750 mg or 0 otherwise. No difference in bioavailability of carbamazepine between controlled and immediate-release tablets was detected. The model predictions in the validation set had no bias and satisfactory precision. The model can be used for estimation of carbamazepine CL/F in individual patients in the postautoinduction phase and for selection of optimum dosing regimen in routine patient care.",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Therapeutic Drug Monitoring",
title = "Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data",
volume = "29",
number = "6",
pages = "781-788",
url = "https://hdl.handle.net/21.15107/rcub_farfar_898"
}

Vučićević, K., Milijković, B., Veličković, R., Pokrajac, M., Mrhar, A.,& Grabnar, I.. (2007). Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. in Therapeutic Drug Monitoring
Lippincott Williams & Wilkins, Philadelphia., 29(6), 781-788.
https://hdl.handle.net/21.15107/rcub_farfar_898

Vučićević K, Milijković B, Veličković R, Pokrajac M, Mrhar A, Grabnar I. Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. in Therapeutic Drug Monitoring. 2007;29(6):781-788.
https://hdl.handle.net/21.15107/rcub_farfar_898 .

Vučićević, Katarina, Milijković, Branislava, Veličković, Ružica, Pokrajac, Milena, Mrhar, Ales, Grabnar, Iztok, "Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data" in Therapeutic Drug Monitoring, 29, no. 6 (2007):781-788,
https://hdl.handle.net/21.15107/rcub_farfar_898 .

TY  - CONF
AU  - Tasić, Ljiljana
AU  - Miljković, Branislava
AU  - Veličković, Ružica
PY  - 2002
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/317
AB  - The Internet is revolutionizing the structure and orienta-
tion of the healthcare market and drug producers, as well.
This new mass media is valuable not only as a source of
information for patients and healthcare providers but
also as a platform for selling products and services (e-commerce). OBJECTIVES: The goal of this study is create
a database of health websites originated from South East
Europe (SEE), and determine the quality of information’s
regarding the customer needs using the World Health
Organization’s (WHO) standard. METHODS: The data-
base, named pluspharma™, was constructed by an
Internet search and an e-mail questionnaire. The quality
of information was measured according to recommenda-
tion of WHO (a rating of 1 to 5). RESULTS: The data-
base contains about 300 web addresses of useful sources
of health and health business information. Of the six
countries (Bosnia and Herzegovina, Bulgaria, Croatia,
Yugoslavia, Macedonia, Romania), Romania showed the
most (37 public health institutions and 26 public tools
promoting health) Web health information sites. The
most websites originated from the primary health care
institutions, government body or pharmaceutical indus-
try. Also, there is the numerous high quality health
promotional website designed with specific task groups
(example tobacco groups). Direct public communication
is evident through about 60% of web sites. Websites of
pharmaceutical industry and pharmacies marking with
relatively high credit (3.89), compared with other health
and service information’s (public and government health
institution). The special task groups (usually evidenced as
NGO) obtained high credit (4.74) of quality and valuable
of Web information’s. CONCLUSIONS: Health-related
websites from South East Europe are becoming good
tools for health promotion in the SEE region.
PB  - Elsevier
C3  - Value in Health
T1  - Websites as tools of promoting health in South East Europe
VL  - 5
IS  - 6
SP  - 472
EP  - 472
DO  - 10.1016/S1098-3015(10)61260-0
ER  - 

@conference{
author = "Tasić, Ljiljana and Miljković, Branislava and Veličković, Ružica",
year = "2002",
abstract = "The Internet is revolutionizing the structure and orienta-
tion of the healthcare market and drug producers, as well.
This new mass media is valuable not only as a source of
information for patients and healthcare providers but
also as a platform for selling products and services (e-commerce). OBJECTIVES: The goal of this study is create
a database of health websites originated from South East
Europe (SEE), and determine the quality of information’s
regarding the customer needs using the World Health
Organization’s (WHO) standard. METHODS: The data-
base, named pluspharma™, was constructed by an
Internet search and an e-mail questionnaire. The quality
of information was measured according to recommenda-
tion of WHO (a rating of 1 to 5). RESULTS: The data-
base contains about 300 web addresses of useful sources
of health and health business information. Of the six
countries (Bosnia and Herzegovina, Bulgaria, Croatia,
Yugoslavia, Macedonia, Romania), Romania showed the
most (37 public health institutions and 26 public tools
promoting health) Web health information sites. The
most websites originated from the primary health care
institutions, government body or pharmaceutical indus-
try. Also, there is the numerous high quality health
promotional website designed with specific task groups
(example tobacco groups). Direct public communication
is evident through about 60% of web sites. Websites of
pharmaceutical industry and pharmacies marking with
relatively high credit (3.89), compared with other health
and service information’s (public and government health
institution). The special task groups (usually evidenced as
NGO) obtained high credit (4.74) of quality and valuable
of Web information’s. CONCLUSIONS: Health-related
websites from South East Europe are becoming good
tools for health promotion in the SEE region.",
publisher = "Elsevier",
journal = "Value in Health",
title = "Websites as tools of promoting health in South East Europe",
volume = "5",
number = "6",
pages = "472-472",
doi = "10.1016/S1098-3015(10)61260-0"
}

Tasić, L., Miljković, B.,& Veličković, R.. (2002). Websites as tools of promoting health in South East Europe. in Value in Health
Elsevier., 5(6), 472-472.
https://doi.org/10.1016/S1098-3015(10)61260-0

Tasić L, Miljković B, Veličković R. Websites as tools of promoting health in South East Europe. in Value in Health. 2002;5(6):472-472.
doi:10.1016/S1098-3015(10)61260-0 .

Tasić, Ljiljana, Miljković, Branislava, Veličković, Ružica, "Websites as tools of promoting health in South East Europe" in Value in Health, 5, no. 6 (2002):472-472,
https://doi.org/10.1016/S1098-3015(10)61260-0 . .

TY  - CONF
AU  - Brzaković, Branka
AU  - Pokrajac, Milena
AU  - Martinović, Žarko J.
AU  - Veličković, Ružica
AU  - Miljković, Branislava
AU  - Varagić, V.M.
PY  - 2002
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/363
PB  - Savez farmaceutskih udruženja Srbije, Beograd
C3  - Arhiv za farmaciju
T1  - Disposition of Lamotrigine in children with epilepsy receiving politherapy
T1  - Dispozicija Lamotrigina u kombinovano terapiji dece sa epilepsijom
VL  - 52
IS  - 4
SP  - 668
EP  - 669
UR  - https://hdl.handle.net/21.15107/rcub_farfar_363
ER  - 

@conference{
author = "Brzaković, Branka and Pokrajac, Milena and Martinović, Žarko J. and Veličković, Ružica and Miljković, Branislava and Varagić, V.M.",
year = "2002",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Disposition of Lamotrigine in children with epilepsy receiving politherapy, Dispozicija Lamotrigina u kombinovano terapiji dece sa epilepsijom",
volume = "52",
number = "4",
pages = "668-669",
url = "https://hdl.handle.net/21.15107/rcub_farfar_363"
}

Brzaković, B., Pokrajac, M., Martinović, Ž. J., Veličković, R., Miljković, B.,& Varagić, V.M.. (2002). Disposition of Lamotrigine in children with epilepsy receiving politherapy. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 52(4), 668-669.
https://hdl.handle.net/21.15107/rcub_farfar_363

Brzaković B, Pokrajac M, Martinović ŽJ, Veličković R, Miljković B, Varagić V. Disposition of Lamotrigine in children with epilepsy receiving politherapy. in Arhiv za farmaciju. 2002;52(4):668-669.
https://hdl.handle.net/21.15107/rcub_farfar_363 .

Brzaković, Branka, Pokrajac, Milena, Martinović, Žarko J., Veličković, Ružica, Miljković, Branislava, Varagić, V.M., "Disposition of Lamotrigine in children with epilepsy receiving politherapy" in Arhiv za farmaciju, 52, no. 4 (2002):668-669,
https://hdl.handle.net/21.15107/rcub_farfar_363 .

TY  - JOUR
AU  - Timotijević-Marković, Ivana
AU  - Pokrajac, Milena
AU  - Miljković, Branislava
AU  - Stojković, Mirjana
AU  - Veličković, Ružica
PY  - 1992
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/92
AB  - The application of tryciclic antidepressants amitriptyline in the therapy of depression is followed by some side effects both those muscarinic and antihistaminic and alpha-adrenergic effects. The manifested degree of side effects directly correlates with the dosage and concentration in plasma, so that maximal effects are manifested when drug concentration in patient's plasma is maximal. When amitriptyline is used in the therapy an effective drug dosage enabling the maximal therapeutic effect and minimal side effects should be determined. By this the maximal outcome of the therapy is made possible.
PB  - Institut za mentalno zdravlje, Beograd
T2  - Psihijatrija danas
T1  - The clinical pharmacological correlation between amitriptyline dosage and side effects
T1  - Kliničko-farmakološka korelacija doza amitriptilina i neželjenih efekata
VL  - 24
IS  - 3-4
SP  - 231
EP  - 249
UR  - https://hdl.handle.net/21.15107/rcub_farfar_92
ER  - 

@article{
author = "Timotijević-Marković, Ivana and Pokrajac, Milena and Miljković, Branislava and Stojković, Mirjana and Veličković, Ružica",
year = "1992",
abstract = "The application of tryciclic antidepressants amitriptyline in the therapy of depression is followed by some side effects both those muscarinic and antihistaminic and alpha-adrenergic effects. The manifested degree of side effects directly correlates with the dosage and concentration in plasma, so that maximal effects are manifested when drug concentration in patient's plasma is maximal. When amitriptyline is used in the therapy an effective drug dosage enabling the maximal therapeutic effect and minimal side effects should be determined. By this the maximal outcome of the therapy is made possible.",
publisher = "Institut za mentalno zdravlje, Beograd",
journal = "Psihijatrija danas",
title = "The clinical pharmacological correlation between amitriptyline dosage and side effects, Kliničko-farmakološka korelacija doza amitriptilina i neželjenih efekata",
volume = "24",
number = "3-4",
pages = "231-249",
url = "https://hdl.handle.net/21.15107/rcub_farfar_92"
}

Timotijević-Marković, I., Pokrajac, M., Miljković, B., Stojković, M.,& Veličković, R.. (1992). The clinical pharmacological correlation between amitriptyline dosage and side effects. in Psihijatrija danas
Institut za mentalno zdravlje, Beograd., 24(3-4), 231-249.
https://hdl.handle.net/21.15107/rcub_farfar_92

Timotijević-Marković I, Pokrajac M, Miljković B, Stojković M, Veličković R. The clinical pharmacological correlation between amitriptyline dosage and side effects. in Psihijatrija danas. 1992;24(3-4):231-249.
https://hdl.handle.net/21.15107/rcub_farfar_92 .

Timotijević-Marković, Ivana, Pokrajac, Milena, Miljković, Branislava, Stojković, Mirjana, Veličković, Ružica, "The clinical pharmacological correlation between amitriptyline dosage and side effects" in Psihijatrija danas, 24, no. 3-4 (1992):231-249,
https://hdl.handle.net/21.15107/rcub_farfar_92 .